Zobrazeno 1 - 10
of 171
pro vyhledávání: '"Rebecca J. Brown"'
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-11 (2023)
Abstract Background Monogenic insulin resistance (IR) includes lipodystrophy and disorders of insulin signalling. We sought to assess the effects of interventions in monogenic IR, stratified by genetic aetiology. Methods Systematic review using PubMe
Externí odkaz:
https://doaj.org/article/5decb5788abb4bbd9c057675fd67e515
Publikováno v:
Communications Medicine, Vol 4, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/53ff07ee34de460a842499ebadf9b9a9
Autor:
Rebecca J. Brown, Grace H. Panter, Natalie Burden, Edward R. Salinas, Lennart Weltje, James R. Wheeler, Yvonne Wolf, Laurent Lagadic
Publikováno v:
Ecotoxicology and Environmental Safety, Vol 266, Iss , Pp 115563- (2023)
Vitellogenin (VTG), a biomarker for endocrine activity, is a mechanistic component of the regulatory assessment of potential endocrine-disrupting properties of chemicals. This review of VTG data is based on changes reported for 106 substances in stan
Externí odkaz:
https://doaj.org/article/d91bd155976c4a21aaf702312294dc11
Autor:
Aaron S. Mansfield, MD, Rebecca J. Brown, PhD, Cormac Sammon, PhD, Melinda J. Daumont, PhD, Mike McKenna, MSc, Jenine K. Sanzari, PhD, Patrick M. Forde, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 5, Pp 100315- (2022)
Introduction: Given the emergence of combination of programmed cell death protein-1 and CTLA4 pathway blockade as effective treatment options in malignant pleural mesothelioma (MPM), there is interest in the extent to which programmed death-ligand 1
Externí odkaz:
https://doaj.org/article/b9fa5e649d834a6dbc7c76aea0481afa
Autor:
Michael G. Head, Rebecca J. Brown
Publikováno v:
BMC Proceedings, Vol 10, Iss S8, Pp 1-3 (2016)
Abstract The Research Investments in Global Health (ResIn, www.researchinvestments.org ) study analyses funding trends in health research, with a predominant focus on infectious diseases. Since October 2015, the project is funded by the Bill & Melind
Externí odkaz:
https://doaj.org/article/d194a7cb03804306a2001e7196de69f5
Publikováno v:
Annals of Global Health, Vol 82, Iss 3 (2016)
Externí odkaz:
https://doaj.org/article/4a548729731d4ffabce6bdc8dfb38140
Publikováno v:
AACE Clinical Case Reports, Vol 2, Iss 3, Pp e274-e275 (2016)
Externí odkaz:
https://doaj.org/article/aeebd6deb09144b7a5892b2bd9b3347a
Autor:
Omar Isam Darwish, Ahmed M. Gharib, Sami Jeljeli, Nader S. Metwalli, Jenna Feeley, Yaron Rotman, Rebecca J. Brown, Ronald Ouwerkerk, David E. Kleiner, Daniel Stäb, Peter Speier, Ralph Sinkus, Radhouene Neji
Publikováno v:
Investigative Radiology. 58:413-419
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd16c9c1e5550c12a3e3730b849c3b25
https://doi.org/10.1097/rli.0000000000000952
https://doi.org/10.1097/rli.0000000000000952
Autor:
Marissa Lightbourne, Megan Startzell, Kimberley D. Bruce, Brianna Brite, Ranganath Muniyappa, Monica Skarulis, Robert Shamburek, Ahmed M. Gharib, Ronald Ouwerkerk, Mary Walter, Robert H. Eckel, Rebecca J. Brown
Publikováno v:
Journal of Clinical Lipidology. 16:850-862
Partial lipodystrophy (PL) syndromes involve deficiency of adipose tissue, causing severe insulin resistance and hypertriglyceridemia. Apolipoprotein C-III (apoC-III) is elevated in PL and is thought to contribute to hypertriglyceridemia by inhibitin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07f7fc729587191e7377087d23c5b6f3
https://doi.org/10.1016/j.jacl.2022.06.011
https://doi.org/10.1016/j.jacl.2022.06.011
Publikováno v:
Endocr Pract
Severe insulin resistance syndromes, such as lipodystrophy, lead to diabetes, which is challenging to control. This study explored the safety and efficacy of sodium-glucose cotransporter 2 inhibitors (SGLT2is) in a series of 12 patients with severe i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d9de89dd96ba3c297f300ab7082377c
https://doi.org/10.1016/j.eprac.2022.03.006
https://doi.org/10.1016/j.eprac.2022.03.006